SG11201403683PA - Cell-penetrating peptides - Google Patents
Cell-penetrating peptidesInfo
- Publication number
- SG11201403683PA SG11201403683PA SG11201403683PA SG11201403683PA SG11201403683PA SG 11201403683P A SG11201403683P A SG 11201403683PA SG 11201403683P A SG11201403683P A SG 11201403683PA SG 11201403683P A SG11201403683P A SG 11201403683PA SG 11201403683P A SG11201403683P A SG 11201403683PA
- Authority
- SG
- Singapore
- Prior art keywords
- cell
- penetrating peptides
- peptides
- penetrating
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4747—Apoptosis related proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6472—Cysteine endopeptidases (3.4.22)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/22—Cysteine endopeptidases (3.4.22)
- C12Y304/22062—Caspase-9 (3.4.22.62)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Virology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Neurology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11306784 | 2011-12-27 | ||
| PCT/EP2012/076968 WO2013098337A1 (en) | 2011-12-27 | 2012-12-27 | Cell-penetrating peptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201403683PA true SG11201403683PA (en) | 2014-10-30 |
Family
ID=47553033
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201607271SA SG10201607271SA (en) | 2011-12-27 | 2012-12-27 | Cell-penetrating peptides |
| SG11201403683PA SG11201403683PA (en) | 2011-12-27 | 2012-12-27 | Cell-penetrating peptides |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201607271SA SG10201607271SA (en) | 2011-12-27 | 2012-12-27 | Cell-penetrating peptides |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US9353155B2 (en) |
| EP (1) | EP2797616B1 (en) |
| JP (1) | JP6169606B2 (en) |
| KR (1) | KR102071514B1 (en) |
| CN (1) | CN104271147B (en) |
| AU (1) | AU2012360845B2 (en) |
| BR (1) | BR112014016076B1 (en) |
| CA (1) | CA2859712C (en) |
| DK (1) | DK2797616T3 (en) |
| ES (1) | ES2748937T3 (en) |
| IL (1) | IL233280B (en) |
| PL (1) | PL2797616T3 (en) |
| SG (2) | SG10201607271SA (en) |
| WO (1) | WO2013098337A1 (en) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2797617B1 (en) * | 2011-12-27 | 2020-01-22 | Sorbonne Université | Anti-tumor adjuvant therapy |
| EP3016972A2 (en) * | 2013-07-03 | 2016-05-11 | Université Pierre et Marie Curie (Paris 6) | Pro-apoptotic ras and raf peptides |
| EP2868326A1 (en) | 2013-11-04 | 2015-05-06 | Université Pierre et Marie Curie (Paris 6) | Peptide inhibitors of TEAD/YAP-TAZ interaction |
| EP2881472A1 (en) * | 2013-12-09 | 2015-06-10 | Université Pierre et Marie Curie (Paris 6) | A method of predicting a response to an anti-tumor treatment |
| JP6551825B2 (en) * | 2014-02-10 | 2019-07-31 | 公立大学法人首都大学東京 | Chromatin structure regulator |
| CN105315348B (en) * | 2014-06-23 | 2018-10-16 | 天津药物研究院 | A kind of transmembrane polypeptide and its preparation method and application |
| KR101835554B1 (en) | 2014-06-24 | 2018-04-19 | 서울대학교 산학협력단 | Composition comprising C/EBF for promoting differentiation or stability of induced regulatroy T cell and method therefor |
| US20180066241A1 (en) * | 2015-03-31 | 2018-03-08 | Universite Pierre Et Marie Curie (Paris 6) | Pro-apoptotic set and pp2a peptides |
| CN105418733A (en) * | 2015-06-23 | 2016-03-23 | 天津药物研究院有限公司 | Preparation and application of conjugate of cell penetrating polypeptide and antitumor drug |
| US10688153B2 (en) | 2015-11-06 | 2020-06-23 | The Board Of Trustees Of The University Of Illinois | Peptides and method for treatment of cardiac arrest |
| EP3272768A1 (en) * | 2016-07-22 | 2018-01-24 | Université Pierre et Marie Curie (Paris 6) | Chimeric peptides useful in malaria prophylaxis or treatment |
| WO2018114863A1 (en) | 2016-12-22 | 2018-06-28 | Sorbonne Universite | Cell penetrating peptides with improved internalization properties |
| US20200231642A1 (en) * | 2017-02-19 | 2020-07-23 | The National Institute for Biotechnology in the Negev Ltd. | Peptide kinase inhibitors and methods of use thereof |
| US11117930B2 (en) | 2017-02-23 | 2021-09-14 | Adrx, Inc. | Peptide inhibitors of transcription factor aggregation |
| CN106995487B (en) * | 2017-04-17 | 2019-12-03 | 扬州大学 | Application derived from Chicken Infectious Anemia Virus VP1-aa 23-43 polypeptide as high efficiency cell cell-penetrating peptide |
| CN106831957B (en) * | 2017-04-17 | 2019-12-03 | 扬州大学 | A kind of application derived from Chicken Infectious Anemia Virus VP1-aa 1-19 polypeptide as high efficiency cell cell-penetrating peptide |
| CN110997693A (en) | 2017-06-07 | 2020-04-10 | 阿德克斯公司 | Tau aggregation inhibitors |
| AU2018318319A1 (en) | 2017-08-18 | 2020-02-20 | Adrx, Inc. | Tau aggregation peptide inhibitors |
| JP7072381B2 (en) | 2017-12-21 | 2022-05-20 | 株式会社クボタ | Combine control system |
| CN111729070B (en) * | 2020-06-02 | 2021-03-30 | 遵义医科大学珠海校区 | Application of polypeptide FL15 in preparation of antitumor drugs |
| WO2023017976A1 (en) * | 2021-08-09 | 2023-02-16 | 주식회사 쎌트로이 | Cationic cell-penetrating peptide and use thereof |
| CN115028685B (en) * | 2022-06-24 | 2023-10-20 | 张金强 | Cationic bicyclic antibacterial peptide and application thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5468223A (en) | 1992-11-30 | 1995-11-21 | C.N.R.S. Paris | Electrochemotherapy |
| FR2827866B1 (en) * | 2001-07-27 | 2004-12-10 | Pasteur Institut | SYNTHETIC OR NATURAL PEPTIDES BINDING PROTEIN PHOSPHATASE 2A, IDENTIFICATION METHOD AND USES |
| WO2004011595A2 (en) * | 2002-07-26 | 2004-02-05 | Institut Pasteur | Vectors for transferring molecules of interest in target cells |
| WO2006124537A1 (en) * | 2005-05-12 | 2006-11-23 | The Burnham Institute | Compounds that regulate apoptosis |
| US20070184015A1 (en) | 2006-02-03 | 2007-08-09 | Soonkap Hahn | Novel PEGylation agent |
| CN101412747B (en) * | 2008-10-21 | 2011-04-20 | 中国药科大学 | Novel cell-penetrating peptide and uses thereof |
| EP2236603A1 (en) | 2009-03-30 | 2010-10-06 | Universite Pierre Et Marie Curie | Pro-apoptotic peptides |
| EP2797617B1 (en) * | 2011-12-27 | 2020-01-22 | Sorbonne Université | Anti-tumor adjuvant therapy |
-
2012
- 2012-12-27 JP JP2014549469A patent/JP6169606B2/en active Active
- 2012-12-27 AU AU2012360845A patent/AU2012360845B2/en active Active
- 2012-12-27 DK DK12813376.6T patent/DK2797616T3/en active
- 2012-12-27 CA CA2859712A patent/CA2859712C/en active Active
- 2012-12-27 SG SG10201607271SA patent/SG10201607271SA/en unknown
- 2012-12-27 CN CN201280065370.2A patent/CN104271147B/en active Active
- 2012-12-27 PL PL12813376T patent/PL2797616T3/en unknown
- 2012-12-27 ES ES12813376T patent/ES2748937T3/en active Active
- 2012-12-27 EP EP12813376.6A patent/EP2797616B1/en active Active
- 2012-12-27 BR BR112014016076-7A patent/BR112014016076B1/en active IP Right Grant
- 2012-12-27 WO PCT/EP2012/076968 patent/WO2013098337A1/en active Application Filing
- 2012-12-27 SG SG11201403683PA patent/SG11201403683PA/en unknown
- 2012-12-27 KR KR1020147021107A patent/KR102071514B1/en active IP Right Grant
- 2012-12-27 US US14/366,199 patent/US9353155B2/en active Active
-
2014
- 2014-06-19 IL IL233280A patent/IL233280B/en active IP Right Grant
-
2016
- 2016-05-26 US US15/165,754 patent/US9644001B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| DK2797616T3 (en) | 2019-10-07 |
| WO2013098337A1 (en) | 2013-07-04 |
| KR102071514B1 (en) | 2020-01-30 |
| AU2012360845B2 (en) | 2017-05-11 |
| JP2015504050A (en) | 2015-02-05 |
| IL233280B (en) | 2019-08-29 |
| EP2797616B1 (en) | 2019-07-31 |
| US20160257713A1 (en) | 2016-09-08 |
| CA2859712A1 (en) | 2013-07-04 |
| BR112014016076A2 (en) | 2017-06-13 |
| BR112014016076A8 (en) | 2017-07-04 |
| SG10201607271SA (en) | 2016-10-28 |
| KR20140128971A (en) | 2014-11-06 |
| JP6169606B2 (en) | 2017-07-26 |
| ES2748937T3 (en) | 2020-03-18 |
| EP2797616A1 (en) | 2014-11-05 |
| CA2859712C (en) | 2023-09-19 |
| US9353155B2 (en) | 2016-05-31 |
| PL2797616T3 (en) | 2020-03-31 |
| CN104271147A (en) | 2015-01-07 |
| CN104271147B (en) | 2018-01-12 |
| US20140364376A1 (en) | 2014-12-11 |
| AU2012360845A1 (en) | 2014-07-31 |
| IL233280A0 (en) | 2014-08-31 |
| US9644001B2 (en) | 2017-05-09 |
| BR112014016076B1 (en) | 2022-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1243427A1 (en) | Therapeutic peptides | |
| IL233280B (en) | Cell-penetrating peptides | |
| EP2857033A4 (en) | Skin-permeating peptide | |
| GB201012651D0 (en) | Peptides | |
| EP2753641A4 (en) | Neuroprotective cell-penetrating peptides | |
| EP2812347A4 (en) | Autophagy-inducing peptide | |
| GB201111183D0 (en) | Peptide | |
| GB201115910D0 (en) | Peptides | |
| HK1209138A1 (en) | Peptides | |
| EP2627674A4 (en) | Egfr-based peptides | |
| EP2793918A4 (en) | Hdc-sign binding peptides | |
| GB201200555D0 (en) | Peptide | |
| GB201204868D0 (en) | Peptides | |
| HK1187628A1 (en) | Novel peptide | |
| EP2714717A4 (en) | Phoenixin peptides | |
| EP2891663B8 (en) | Psf1-derived peptide | |
| GB201115014D0 (en) | Peptides | |
| AU2011903086A0 (en) | Peptides | |
| GB201220328D0 (en) | Peptides | |
| GB201211740D0 (en) | Peptides | |
| GB201207895D0 (en) | Peptides | |
| GB201200509D0 (en) | Peptides | |
| GB201112985D0 (en) | Polypeptide | |
| GB201112849D0 (en) | Polypeptide | |
| GB201106130D0 (en) | Polypeptide |